ORKA vs IMVT vs REGN vs DAWN vs IQV

For growth investors, Day One Biopharmaceuticals, Inc.

(DAWN) is the stronger pick with 20. 6% revenue growth year-over-year, versus 1. 0% for Regeneron Pharmaceuticals, Inc. (REGN). Regeneron Pharmaceuticals, Inc. (REGN) offers the better valuation at 17. 2x trailing P/E (15. 5x forward), making it the more compelling value choice. Analysts rate Oruka Therapeutics, Inc. (ORKA) a "Buy" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Regeneron Pharmaceuticals, Inc.

(REGN) is the cheapest at 17. 2x versus IQVIA Holdings Inc. at 22. 8x. On forward P/E, IQVIA Holdings Inc. is actually cheaper at 14. 0x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: IQVIA Holdings Inc. wins at 0. 34x versus Regeneron Pharmaceuticals, Inc. 's 2. 44x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Oruka Therapeutics, Inc.

(ORKA) delivered a total return of +128. 6%, compared to -22. 8% for IQVIA Holdings Inc. (IQV). Over 10 years, the gap is even starker: IMVT returned +190. 9% versus ORKA's -89. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Day One Biopharmaceuticals, Inc.

(DAWN) is the lower-risk stock at 0. 25β versus Oruka Therapeutics, Inc. 's 1. 50β — meaning ORKA is approximately 492% more volatile than DAWN relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 2% for IQVIA Holdings Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Day One Biopharmaceuticals, Inc.

(DAWN) is pulling ahead at 20. 6% versus 1. 0% for Regeneron Pharmaceuticals, Inc. (REGN). On earnings-per-share growth, the picture is similar: Oruka Therapeutics, Inc. grew EPS 39. 7% year-over-year, compared to -45. 2% for Immunovant, Inc.. Over a 3-year CAGR, REGN leads at 5. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Regeneron Pharmaceuticals, Inc.

(REGN) is the more profitable company, earning 31. 4% net margin versus -67. 8% for Day One Biopharmaceuticals, Inc. — meaning it keeps 31. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: REGN leads at 24. 9% versus -80. 8% for DAWN. At the gross margin level — before operating expenses — DAWN leads at 89. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, IQVIA Holdings Inc. (IQV) is the more undervalued stock at a PEG of 0. 34x versus Regeneron Pharmaceuticals, Inc. 's 2. 44x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, IQVIA Holdings Inc. (IQV) trades at 14. 0x forward P/E versus 15. 5x for Regeneron Pharmaceuticals, Inc. — 1. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ORKA: 111. 1% to $136. 38.

In this comparison, REGN (0.

5% yield) pays a dividend. ORKA, IMVT, DAWN, IQV do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Day One Biopharmaceuticals, Inc.

(DAWN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 25)). Oruka Therapeutics, Inc. (ORKA) carries a higher beta of 1. 50 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (DAWN: -8. 4%, ORKA: -89. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ORKA is a small-cap quality compounder stock; IMVT is a small-cap quality compounder stock; REGN is a mid-cap deep-value stock; DAWN is a small-cap high-growth stock; IQV is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.